The Oncology Institute, Inc. (NASDAQ:TOI) Sees Large Growth in Short Interest

The Oncology Institute, Inc. (NASDAQ:TOI) was the target of a large growth in short interest in January. As of January 15th, there was short interest totalling 324,100 shares, a growth of 86.8% from the December 31st total of 173,500 shares. Based on an average daily volume of 1,740,000 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.9% of the shares of the stock are sold short.

Insider Buying and Selling

In other Oncology Institute news, Director Brad Hively bought 250,000 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The shares were bought at an average price of $0.17 per share, for a total transaction of $42,500.00. Following the completion of the acquisition, the director now owns 616,753 shares of the company’s stock, valued at approximately $104,848.01. This trade represents a 68.17 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. 9.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Oncology Institute stock. HighTower Advisors LLC boosted its position in shares of The Oncology Institute, Inc. (NASDAQ:TOI) by 190.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 81,362 shares of the company’s stock after purchasing an additional 53,382 shares during the quarter. HighTower Advisors LLC owned about 0.11% of Oncology Institute worth $27,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 36.86% of the company’s stock.

Oncology Institute Price Performance

NASDAQ TOI traded down $0.01 on Friday, hitting $1.00. 1,568,685 shares of the company were exchanged, compared to its average volume of 986,129. The firm has a 50 day moving average of $0.34 and a two-hundred day moving average of $0.35. The company has a market cap of $75.56 million, a P/E ratio of -1.28 and a beta of 0.13. The company has a current ratio of 2.49, a quick ratio of 2.27 and a debt-to-equity ratio of 5.91. Oncology Institute has a 1-year low of $0.13 and a 1-year high of $2.20.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.